Avantax Advisory Services Inc. Decreases Holdings in Hims & Hers Health, Inc. (NYSE:HIMS)

Avantax Advisory Services Inc. decreased its holdings in Hims & Hers Health, Inc. (NYSE:HIMS - Free Report) by 19.4% during the 1st quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The fund owned 21,329 shares of the company's stock after selling 5,127 shares during the quarter. Avantax Advisory Services Inc.'s holdings in Hims & Hers Health were worth $630,000 at the end of the most recent reporting period.

Several other institutional investors also recently modified their holdings of HIMS. American Century Companies Inc. raised its holdings in shares of Hims & Hers Health by 8.8% in the 4th quarter. American Century Companies Inc. now owns 140,758 shares of the company's stock worth $3,404,000 after acquiring an additional 11,425 shares during the last quarter. LPL Financial LLC grew its position in shares of Hims & Hers Health by 1.0% during the 4th quarter. LPL Financial LLC now owns 97,958 shares of the company's stock valued at $2,369,000 after acquiring an additional 980 shares during the period. Pictet Asset Management Holding SA grew its position in shares of Hims & Hers Health by 26.9% during the 4th quarter. Pictet Asset Management Holding SA now owns 23,129 shares of the company's stock valued at $559,000 after acquiring an additional 4,898 shares during the period. O Shaughnessy Asset Management LLC bought a new position in Hims & Hers Health in the 4th quarter worth approximately $208,000. Finally, National Bank of Canada FI boosted its holdings in Hims & Hers Health by 438.7% in the 4th quarter. National Bank of Canada FI now owns 2,990 shares of the company's stock worth $72,000 after buying an additional 2,435 shares during the period. Institutional investors own 63.52% of the company's stock.

Hims & Hers Health Stock Down 12.5%

Shares of NYSE HIMS traded down $7.89 during trading hours on Tuesday, hitting $55.46. 105,644,426 shares of the stock were exchanged, compared to its average volume of 32,693,628. The company has a market cap of $12.41 billion, a PE ratio of 69.33, a PEG ratio of 2.34 and a beta of 2.08. The firm has a fifty day moving average price of $53.79 and a 200-day moving average price of $44.51. Hims & Hers Health, Inc. has a 12 month low of $13.47 and a 12 month high of $72.98.

Hims & Hers Health (NYSE:HIMS - Get Free Report) last released its earnings results on Monday, August 4th. The company reported $0.17 earnings per share for the quarter, missing the consensus estimate of $0.18 by ($0.01). The company had revenue of $544.83 million for the quarter, compared to analysts' expectations of $550.06 million. Hims & Hers Health had a return on equity of 27.26% and a net margin of 9.63%. The firm's revenue for the quarter was up 72.6% on a year-over-year basis. During the same period in the prior year, the firm posted $0.06 EPS. As a group, equities analysts anticipate that Hims & Hers Health, Inc. will post 0.29 earnings per share for the current fiscal year.

Analyst Upgrades and Downgrades

HIMS has been the subject of several analyst reports. UBS Group set a $30.00 price target on shares of Hims & Hers Health in a report on Monday, June 23rd. Deutsche Bank Aktiengesellschaft reiterated a "hold" rating on shares of Hims & Hers Health in a research report on Wednesday, May 7th. Wall Street Zen cut shares of Hims & Hers Health from a "buy" rating to a "hold" rating in a research report on Monday, July 28th. Truist Financial upped their target price on shares of Hims & Hers Health from $45.00 to $48.00 and gave the stock a "hold" rating in a research note on Thursday, July 17th. Finally, Bank of America upped their target price on shares of Hims & Hers Health from $22.00 to $26.00 and gave the stock an "underperform" rating in a research note on Tuesday, April 29th. Three research analysts have rated the stock with a sell rating, nine have issued a hold rating and two have issued a buy rating to the company. According to data from MarketBeat, the company presently has a consensus rating of "Hold" and an average price target of $39.83.

Insider Buying and Selling at Hims & Hers Health

In related news, CFO Oluyemi Okupe sold 11,581 shares of the stock in a transaction on Monday, July 14th. The shares were sold at an average price of $47.70, for a total transaction of $552,413.70. Following the sale, the chief financial officer directly owned 54,084 shares of the company's stock, valued at approximately $2,579,806.80. This represents a 17.64% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is available at this hyperlink. Also, CEO Andrew Dudum sold 125,335 shares of the company's stock in a transaction dated Monday, July 21st. The stock was sold at an average price of $49.54, for a total transaction of $6,209,095.90. Following the completion of the transaction, the chief executive officer owned 92,313 shares of the company's stock, valued at approximately $4,573,186.02. This trade represents a 57.59% decrease in their position. The disclosure for this sale can be found here. Insiders sold 737,704 shares of company stock valued at $40,644,035 over the last quarter. Insiders own 17.71% of the company's stock.

Hims & Hers Health Profile

Hims & Hers Health, Inc operates a telehealth consultation platform. It connects consumers to healthcare professionals, enabling them to access medical care for mental health, sexual health, dermatology and primary care. The company was founded in 2017 and is headquartered in San Francisco, CA.